Treatment of myasthenia gravis with high-dose intravenous immunoglobulin

V. Cosi, M. Lombardi, G. Piccolo, A. Erbetta

Research output: Contribution to journalArticlepeer-review


We treated 37 patients affected by autoimmune generalized myasthenia gravis (MG) with high-dose intravenous gammaglobulin (HDIVIg), 400 mg/kg per day on 5 consecutive days. A one-degree improvement of Oosterhuis global clinical classification of myasthenic severity (OGCCMS), the disappearance of bulbar involvement or both were recorded 12 days after the beginning of the treatment in 70.3% of the patients and persisted up to 60 days in 58.7%. A two-degree improvement of OGCCMS was recorded in 54.1% of the patients and it was maintained up to 60 days in 37.8%. The percentage of improvement did not significantly differ between patients entering the treatment in a long-standing, drug-refractory stationary phase of the illness (n = 26) and patients who received HDIVIg in an acute phase of MG (n = 11). None of the patients experienced side effects. Our data indicates that HDIVIg is an interesting, virtually riskless therapeutic choice for MG patients, and allows the planning of a controlled trial versus plasma-exchange.

Original languageEnglish
Pages (from-to)81-84
Number of pages4
JournalActa Neurologica Scandinavica
Issue number2
Publication statusPublished - 1991


  • high-dose
  • immunoglobulin
  • intravenous
  • Myasthenia gravis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Treatment of myasthenia gravis with high-dose intravenous immunoglobulin'. Together they form a unique fingerprint.

Cite this